Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056). / Sørensen, J B; Groth, S; Hansen, S W; Nissen, Mogens Holst; Rørth, M; Hansen, H H.
In: Cancer Chemotherapy and Pharmacology, Vol. 15, No. 2, 1985, p. 97-100.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).
AU - Sørensen, J B
AU - Groth, S
AU - Hansen, S W
AU - Nissen, Mogens Holst
AU - Rørth, M
AU - Hansen, H H
N1 - Keywords: Adult; Aged; Drug Evaluation; Female; Humans; Iodohippuric Acid; Kidney Tubules; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Pentetic Acid; Proteinuria; Technetium; Technetium Tc 99m Pentetate; Thrombocytopenia
PY - 1985
Y1 - 1985
N2 - The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mild, reversible tubular damage was found. Dose-limiting toxicity was hematologic with both thrombopenia and leukocytopenia, which with high dose levels reached WHO grade 4. Hematologic toxicity was most pronounced for pretreated patients. No antitumor activity was seen. The recommended dose for phase II trials will be 9.0 mg/m2 for previously untreated and 8.0 mg/m2 for pretreated patients.
AB - The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mild, reversible tubular damage was found. Dose-limiting toxicity was hematologic with both thrombopenia and leukocytopenia, which with high dose levels reached WHO grade 4. Hematologic toxicity was most pronounced for pretreated patients. No antitumor activity was seen. The recommended dose for phase II trials will be 9.0 mg/m2 for previously untreated and 8.0 mg/m2 for pretreated patients.
M3 - Journal article
C2 - 3893780
VL - 15
SP - 97
EP - 100
JO - Cancer Chemotherapy and Pharmacology, Supplement
JF - Cancer Chemotherapy and Pharmacology, Supplement
SN - 0943-9404
IS - 2
ER -
ID: 8746841